Johnson & Johnson Secures Extended NICE Approval for Darzalex
NICE has preliminarily recommended the use of D-VRd (Darzalex plus VRd) as a first-line treatment for transplant-ineligible multiple myeloma patients. This decision follows an earlier refusal and expands access to Johnson & Johnson's Darzalex on the NHS.
Johnson & Johnson (NYSE: JNJ) announced that the National Institute for Health and Care Excellence (NICE) has preliminarily recommended the use of D-VRd (Darzalex plus VRd) as a first-line treatment for transplant-ineligible multiple myeloma patients. The decision reverses a previous refusal and expands access to Darzalex on the NHS.
Details of the Action
NICE preliminarily recommended D-VRd as a first-line treatment option for transplant-ineligible multiple myeloma patients. The recommendation follows a review of clinical trial data demonstrating the regimen's efficacy.
Company's Position
Johnson & Johnson welcomed the decision, viewing it as a positive step toward expanding patient access to Darzalex. The company reaffirmed its commitment to providing innovative treatment options.
Precedents and Context
NICE had previously refused approval for D-VRd for the same indication but revised its stance after additional evidence was submitted. This decision is significant as it allows earlier use of Darzalex, potentially improving patient outcomes.
Potential Financial Impact
The expanded approval is expected to boost Darzalex sales in the UK, though the overall financial impact on JNJ may be limited given the UK market's small share of global revenues.
Frequently Asked Questions
Found this useful? Share it